^
    3d
    Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma (clinicaltrials.gov)
    P3, N=1449, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    Proleukin (aldesleukin) • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)
    4d
    Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2024 --> Apr 2025
    Trial completion date • Surgery
    |
    Leukine (sargramostim) • Panvac-VF (falimarev/inalimarev)
    6d
    Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System (clinicaltrials.gov)
    P3, N=70, Completed, Children's Oncology Group | Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Mar 2024
    Trial completion • Trial completion date • Surgery
    |
    cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • leucovorin calcium • thiotepa • Neupogen (filgrastim)
    6d
    Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma (clinicaltrials.gov)
    P2, N=24, Completed, Fundació Sant Joan de Déu | Unknown status --> Completed
    Trial completion
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    Unituxin (dinutuximab) • Leukine (sargramostim)
    11d
    NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Sep 2024
    Trial completion date
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • IL6 (Interleukin 6) • CXCL9 (Chemokine (C-X-C motif) ligand 9)
    |
    MYCN amplification • IL6 expression
    |
    cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • dexrazoxane
    13d
    Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. (PubMed, J Immunother Cancer)
    Our findings illustrate that G47Δ-mIL2 is efficacious, stimulates antitumor immunity against orthotopic GBM, and may also target GSC. OHSV expressing IL-2 may represent an agent that merits further exploration in patients with GBM.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • CSF2 (Colony stimulating factor 2)
    |
    IL2 expression
    |
    Imlygic (talimogene laherparepvec)
    14d
    GM-CSF With Post-Transplant Cyclophosphamide (clinicaltrials.gov)
    P2, N=38, Recruiting, Northside Hospital, Inc. | Trial completion date: May 2025 --> Sep 2025 | Trial primary completion date: May 2024 --> Sep 2024
    Trial completion date • Trial primary completion date • Post-transplantation
    |
    cyclophosphamide • Leukine (sargramostim)
    17d
    A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors (clinicaltrials.gov)
    P2, N=19, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Feb 2024 | Trial primary completion date: Jun 2024 --> Feb 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Imlygic (talimogene laherparepvec)
    19d
    SESAD: Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease (clinicaltrials.gov)
    P2, N=42, Recruiting, University of Colorado, Denver | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    Leukine (sargramostim)
    23d
    Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (clinicaltrials.gov)
    P1/2, N=10, Enrolling by invitation, National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    |
    CD34 (CD34 molecule)
    |
    busulfan • Kepivance (palifermin) • Neupogen (filgrastim) • plerixafor
    24d
    Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    cisplatin • paclitaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • melphalan • Neupogen (filgrastim)
    24d
    Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=245, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Surgery • Metastases
    |
    Yervoy (ipilimumab) • Leukine (sargramostim)
    24d
    A Case of CD4+ T-Cell Lymphoma With Gamma-Delta Phenotype, Incidentally Manifesting in a Wound Debridement Sample. (PubMed, Am J Dermatopathol)
    The patient was started on mini-CHOP and filgrastim; however, the patient died within 1 month after the diagnosis. This is an interesting case of gamma-delta T-cell lymphoma that was incidentally diagnosed on a chronic wound. In addition, it showed a CD4+, CD8- phenotype that is exceedingly rare for T-cell lymphomas with gamma-delta phenotype.
    Journal
    |
    CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Neupogen (filgrastim)
    1m
    OH2 oncolytic virus: A novel approach to glioblastoma intervention through direct targeting of tumor cells and augmentation of anti-tumor immune responses. (PubMed, Cancer Lett)
    Significantly, these discoveries have driven the initiation of a phase I/II clinical trial (ClinicalTrials.gov: NCT05235074). This trial is designed to explore the potential of OH2 as a therapeutic option for patients with recurrent central nervous system tumors following surgical intervention.
    Journal • Oncolytic virus • IO biomarker • Tumor cell
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD8 (cluster of differentiation 8) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD4 (CD4 Molecule)
    |
    CDKN2A deletion • CDKN2A mutation
    |
    BS001
    1m
    Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07). (clinicaltrials.gov)
    P2, N=72, Completed, Amgen | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Imlygic (talimogene laherparepvec)
    1m
    Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma (clinicaltrials.gov)
    P1, N=24, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD4 (CD4 Molecule)
    |
    paclitaxel • Neupogen (filgrastim)
    1m
    Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (clinicaltrials.gov)
    P1/2, N=10, Not yet recruiting, National Institute of Allergy and Infectious Diseases (NIAID)
    New P1/2 trial
    |
    CD34 (CD34 molecule)
    |
    busulfan • Kepivance (palifermin) • Neupogen (filgrastim) • plerixafor
    2ms
    Inducing expression of ICOS-L by oncolytic adenovirus to enhance tumor-specific bi-specific antibody efficacy. (PubMed, J Transl Med)
    Together, our data suggests that oncolytic adenoviruses encoding ICOSL may enhance functional activity of tumor-specific BsAbs thereby opening a novel avenue for clinical development in immunotherapeutics.
    Journal • Oncolytic virus • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • ICOS (Inducible T Cell Costimulator) • CSF2 (Colony stimulating factor 2)
    |
    ONCOS-102
    2ms
    Comparison of the oncolytic activity of a replication-competent and a replication-deficient herpes simplex virus 1. (PubMed, Immunology)
    T-VEC was oncolytic for an extended period of time as viral replication continued, which could be partially blocked by the antiviral drug aciclovir. When markers of immunogenic cell death were assessed, ATP was released more efficiently in the context of T-VEC than HSV-1 d106S infection, whereas HMGB1 was induced comparatively well. Overall, the early oncolytic effect on three different tumour entities was stronger with the non-replicative strain, while the replication-competent virus elicited a stronger innate immune response and more pronounced immunogenic cell death.
    Journal
    |
    HMGB1 (High Mobility Group Box 1) • CASP7 (Caspase 7) • IFNB1 (Interferon Beta 1)
    |
    Imlygic (talimogene laherparepvec)
    2ms
    Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma (clinicaltrials.gov)
    P3, N=107, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Jan 2024 --> Jan 2025
    Trial completion date
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • Neupogen (filgrastim)
    2ms
    GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=28, Completed, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Feb 2024 | Trial primary completion date: Sep 2024 --> Feb 2024
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy
    |
    CD8 (cluster of differentiation 8)
    |
    Opdivo (nivolumab) • cyclophosphamide • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)
    2ms
    Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide. (PubMed, Mol Cancer)
    Analysis of sequential tissue biopsies and plasma samples revealed an increase in CD8 density and upregulation of immune-related protein biomarkers, including CXCL10.Intra-tumoral administration of JX-594 in combination with cyclophosphamide and avelumab is safe and capable of modulating the TME in cold STS. However, the limited efficacy observed warrants further research to define the therapeutic potential of oncolytic viruses, particularly in relation to specific histological subtypes of STS.
    P2 data • Journal • Oncolytic virus • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10)
    |
    Bavencio (avelumab) • cyclophosphamide • Pexa-Vec (pexastimogene devacirepvec)
    2ms
    Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases (clinicaltrials.gov)
    P1, N=36, Completed, Amgen | Phase classification: P1b --> P1
    Phase classification • Combination therapy
    |
    Tecentriq (atezolizumab) • Imlygic (talimogene laherparepvec)
    2ms
    Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov)
    P1/2, N=217, Completed, Amgen | Phase classification: P1b/2 --> P1/2
    Phase classification
    |
    BRAF (B-raf proto-oncogene) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    BRAF mutation • BRAF wild-type
    |
    Yervoy (ipilimumab) • Imlygic (talimogene laherparepvec)
    2ms
    Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (clinicaltrials.gov)
    P1, N=40, Recruiting, Stanford University | Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Jakafi (ruxolitinib) • cyclophosphamide • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim) • plerixafor
    2ms
    NCI-2011-00344: Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=8, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    Rituxan (rituximab) • Neupogen (filgrastim) • plerixafor
    2ms
    A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Ossium Health, Inc. | Trial completion date: Dec 2025 --> Aug 2025
    Trial completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • fludarabine IV • Neupogen (filgrastim)
    2ms
    Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • BMS-813160 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)
    2ms
    Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Gene therapy
    |
    CD34 (CD34 molecule)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • etoposide oral • vincristine • prednisone • Neupogen (filgrastim)
    3ms
    Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. (PubMed, Sci Adv)
    Adding SBRT to GVAX/a-PD-1 shortens the distances from PD-1+CD8+ T cells to tumor cells and to PD-L1+ myeloid cells, which portends prolonged survival. These findings have guided the design of next radioimmunotherapy studies by targeting M2-like TAM in PDACs.
    Journal • Tumor cell
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • GZMB (Granzyme B)
    |
    GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)
    3ms
    Study of CG0070 After Transurethral Resection in Patients With IR NMIBC (clinicaltrials.gov)
    P1, N=20, Recruiting, H. Lee Moffitt Cancer Center and Research Institute
    New P1 trial
    |
    cretostimogene grenadenorepvec (CG0070)
    3ms
    Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for Cancer. (PubMed, Cancers (Basel))
    In a prospective, randomized study (ECOG 1608), advanced melanoma patients had a reduction in grade 3-5 GI irAEs and less frequent colonic perforation in the sargramostim plus ipilimumab arm compared to ipilimumab alone. Sargramostim continues to be studied with ICIs for the prophylactic management of irAEs while also potentially providing a survival benefit.
    Review • Journal • Adverse events • Checkpoint inhibition
    |
    CSF2 (Colony stimulating factor 2)
    |
    Yervoy (ipilimumab) • Leukine (sargramostim)
    3ms
    Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor (clinicaltrials.gov)
    P3, N=416, Completed, St. Jude Children's Research Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 negative • HER-2 expression
    |
    cisplatin • cyclophosphamide • vincristine • Neupogen (filgrastim)
    3ms
    Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov)
    P1, N=12, Completed, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active, not recruiting --> Completed
    Trial completion • Combination therapy
    |
    Keytruda (pembrolizumab) • cyclophosphamide • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • LY3022855
    3ms
    Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin (clinicaltrials.gov)
    P1, N=5, Completed, Rutgers, The State University of New Jersey | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Feb 2023 | Trial primary completion date: Sep 2024 --> Feb 2023
    Trial completion • Trial completion date • Trial primary completion date • Tumor mutational burden • Metastases
    |
    Vectibix (panitumumab) • Imlygic (talimogene laherparepvec)
    4ms
    Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Mayo Clinic | Trial completion date: Jan 2025 --> Apr 2025 | Initiation date: Dec 2023 --> Mar 2024 | Trial primary completion date: Jan 2025 --> Apr 2025
    Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Leukine (sargramostim)
    4ms
    CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P1, N=120, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cytarabine • cyclophosphamide • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    4ms
    A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Ossium Health, Inc.
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • fludarabine IV • mesna • busulfan • Neupogen (filgrastim)
    4ms
    Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (clinicaltrials.gov)
    P1, N=40, Recruiting, Stanford University
    Trial completion date • Trial primary completion date • Metastases
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • melphalan • fludarabine IV • Neupogen (filgrastim) • plerixafor
    4ms
    A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy (clinicaltrials.gov)
    P2, N=83, Recruiting, Tufts Medical Center
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • Leukine (sargramostim)
    4ms
    A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, Memorial Sloan Kettering Cancer Center
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Imlygic (talimogene laherparepvec)
    4ms
    Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P2, N=270, Recruiting, M.D. Anderson Cancer Center | N=200 --> 270
    Enrollment change
    |
    cytarabine • decitabine • Mylotarg (gemtuzumab ozogamicin) • idarubicin hydrochloride • fludarabine IV • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)